Germany · Delayed Price · Currency is EUR Northwest Biotherapeutics Statistics
Total Valuation
BST:NBYB has a market cap or net worth of EUR 321.78 million. The enterprise value is 390.68 million.
| Market Cap | 321.78M |
| Enterprise Value | 390.68M |
Important Dates
The next estimated earnings date is Monday, August 11, 2025.
| Earnings Date | Aug 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 1.47B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +11.99% |
| Shares Change (QoQ) | +3.97% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.36B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 236.12 |
| PB Ratio | -4.10 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.91 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -7.69 |
Financial Position
The company has a current ratio of 0.06
| Current Ratio | 0.06 |
| Quick Ratio | 0.03 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.26 |
| Interest Coverage | -8.67 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -151.76% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 122.54% |
| Revenue Per Employee | 54,513 |
| Profits Per Employee | -3.18M |
| Employee Count | 25 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.43% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -34.43% |
| 50-Day Moving Average | 0.23 |
| 200-Day Moving Average | 0.25 |
| Relative Strength Index (RSI) | 55.68 |
| Average Volume (20 Days) | 22,959 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 19.04 |
Income Statement
In the last 12 months, BST:NBYB had revenue of EUR 1.36 million and -79.49 million in losses. Loss per share was -0.06.
| Revenue | 1.36M |
| Gross Profit | -31.29M |
| Operating Income | -62.98M |
| Pretax Income | -78.47M |
| Net Income | -79.49M |
| EBITDA | -61.36M |
| EBIT | -62.98M |
| Loss Per Share | -0.06 |
Balance Sheet
The company has 2.57 million in cash and 63.84 million in debt, giving a net cash position of -61.27 million.
| Cash & Cash Equivalents | 2.57M |
| Total Debt | 63.84M |
| Net Cash | -61.27M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -78.49M |
| Book Value Per Share | -0.07 |
| Working Capital | -72.51M |
Cash Flow
In the last 12 months, operating cash flow was -49.99 million and capital expenditures -803,074, giving a free cash flow of -50.79 million.
| Operating Cash Flow | -49.99M |
| Capital Expenditures | -803,074 |
| Free Cash Flow | -50.79M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -4,621.52% |
| Pretax Margin | -5,757.57% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BST:NBYB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.99% |
| Shareholder Yield | n/a |
| Earnings Yield | -24.70% |
| FCF Yield | -15.78% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BST:NBYB has an Altman Z-Score of -83.67 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -83.67 |
| Piotroski F-Score | 2 |